Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study.

导出原文传递

翻译打印收藏纠错

第一作者： Arnon P,Kater

第一单位： 1 Amsterdam Universitair Medische Centra, University of Amsterdam, Amsterdam, the Netherlands.

作者： Arnon P,Kater ^[1] ; John F,Seymour ^[2] ; Peter,Hillmen ^[3] ; Barbara,Eichhorst ^[4] ; Anton W,Langerak ^[5] ; Carolyn,Owen ^[6] ; Maria,Verdugo ^[7] ; Jenny,Wu ^[8] ; Elizabeth A,Punnoose ^[8] ; Yanwen,Jiang ^[8] ; Jue,Wang ^[8] ; Michelle,Boyer ^[9] ; Kathryn,Humphrey ^[9] ; Mehrdad,Mobasher ^[8] ; Thomas J,Kipps ^[10]

作者单位： 1 Amsterdam Universitair Medische Centra, University of Amsterdam, Amsterdam, the Netherlands. ^[1] 2 Royal Melbourne Hospital and University of Melbourne, Melbourne, Victoria, Australia. ^[2] 3 St James's University Hospital, Leeds, United Kingdom. ^[3] 4 University of Cologne, Cologne, Germany. ^[4] 5 Erasmus MC University Medical Center, Rotterdam, the Netherlands. ^[5] 6 University of Calgary, Calgary, Alberta, Canada. ^[6] 7 AbbVie, North Chicago, IL. ^[7] 8 Genentech, South San Francisco, CA. ^[8] 9 Roche Products Limited, Welwyn Garden City, United Kingdom. ^[9] 10 University of California School of Medicine, San Diego, CA. ^[10]